The problem has never been the efficacy of Penthrox, its always been the uptake from hospitals, ambos etc. That's our real problem.
I haven't heard anything from MVP about how they plan to deal with that problem either, perhaps because they outsource distribution and think that is good enough.
Yet another favorable report, page-3
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
-0.010(2.20%) |
Mkt cap ! $50.13M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 46.0¢ | 43.0¢ | $141.5K | 317.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 15758 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 402 | 1 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| MVP (ASX) Chart |